Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
096760.KS
Strong BuyFull HouseAPPROVEJW Holdings Corporation · Healthcare · South Korea · $209M · Avg Vol: $327K/d
JW Holdings exhibits clear insider conviction through recent material buying, signaling alignment between management and shareholders. As a specialized healthcare player, it benefits from inelastic demand for essential medical products. The company's focus on clinical resilience allows it to compound value independently of broader macro equity volatility.
COMPANY DESCRIPTION
JW Holdings Corporation is the holding company for the JW Group, overseeing a portfolio of healthcare subsidiaries specialized in pharmaceuticals, medical devices, and diagnostics. Through its key operating units, the company commands a dominant, near-monopoly position in South Korea's essential intravenous (IV) fluid market. It leverages a vertically integrated business model to drive synergies across drug discovery, manufacturing, and global distribution.
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 864.5B | 928.1B | 887.7B | 969.6B | 3.9% | 1.0T |
| EPS (KRW) | 306.49 | 265.00 | 874.00 | 841.00 | 40.0% | 846.77 |
| Shares | 72.3M | 70.8M | 70.7M | 69.2M | -4.3% | 69.2M |
| Debt | 552.0B | 554.6B | 435.9B | 359.6B | -13.3% | 359.5B |
| Equity | 107.0B | 124.0B | 229.5B | 267.0B | 35.6% | — |
| Op CF | 104.4B | 112.3B | 97.9B | 163.7B | 16.2% | 209.5B |
| Inv CF | -107.0B | -69.2B | 17.7B | -24.7B | — | — |
| Fin CF | 16.8B | -29.1B | -141.4B | -111.5B | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 096760.KS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 096760.KS | JW Holdings Corporation(you) | $209M | 100 | Strong Buy |
| 005500.KS | Samjin Pharmaceuticals Co., Ltd. | $170M | 93 | Strong Buy |
| 033270.KS | Korea United Pharm Inc. | $188M | 88 | Strong Buy |
| 016580.KS | Whan In Pharm Co.,Ltd. | $137M | 94 | Strong Buy |
| 234080.KS | JW Lifescience Corporation | $128M | 93 | Strong Buy |
| 001540.KQ | Ahn-Gook Pharmaceutical Co., Ltd. | $91M | 100 | Strong Buy |
| 001060.KS | JW Pharmaceutical Corporation | $461M | 94 | Strong Buy |
| 023910.KQ | Daihan Pharmaceutical Co.,Ltd. | $116M | 89 | Strong Buy |
| 008490.KS | Suheung Co., Ltd. | $186M | 80 | Buy |
| 001630.KS | Chong Kun Dang Holdings Corp. | $136M | 86 | Strong Buy |
Peer medians: ROE -0.3% · P/E 16.2x · Gross margin 43.0%